Survival from uveal melanoma in England and Wales 1986 to 2001

Ophthalmic Epidemiology

Volumn 14, Issue 1, 2007, Pages 3-8

  Burr, J M ^a   Mitry, E ^b   Rachet, B ^c   Coleman, M P ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b HÔPITAL AMBROISE PARÉ   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Age; Melanoma; Poverty; Survival; Uveal

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; EYE CANCER; EYELID TUMOR; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POVERTY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RESIDENTIAL HOME; SEX DIFFERENCE; SEX RATIO; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UNITED KINGDOM; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ENGLAND; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MELANOMA; MIDDLE AGED; REGISTRIES; SURVIVAL RATE; UVEAL NEOPLASMS; WALES;

EID: 33847386259     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286580600977281     Document Type: Article

References (45)

1. Stang A, Parkin DM, Ferlay J, et al. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. Int J Cancer. 2005;114(1):114-123.
2. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11(3):255-263.
3. Brandberg Y, Kock E, Oskar K, Trampe E, Seregard S. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye. 2000;14(6):839-846.
4. Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U, Ragnarsson-Olding B. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2003;44:3282-3287.
5. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: Surv Ophthalmol. 1996;41(3):215-228.
6. Singh AD, Damato B, Howard P, et al. Uveal melanoma: Genetic aspects. Ophthalmol Clin North Am. 2005;18(1):85-97.
7. Bergman L, Nilsson B, Lundell G, et al. Ruthenium brachytherapy for uveal melanoma, 1979-2003: Survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834-840.
8. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:962-965.
9. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III Initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
10. Department of Health. National Specialist Commissioning Advisory Group. http://www.dh.gov.uk/, accesses December 2004
11. Sikora K. Cancer survival in Britain is poorer than that of her comparable European neighbours. BMJ. 1999;319(7208):461-462.
12. World Health Organisation. International Classification of Diseases for Oncology (ICD-O), 2nd ed. Geneva: WHO, 1990.
13. World Health Organisation. International Classification of Diseases, 1975, 9th revision. Geneva: WHO, 1977.
14. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 1989, 10th revision. Geneva, WHO, 1992.
15. Carstairs V. Deprivation indices: their interpretation and use in relation to health. J Epidemiol Community Health. 1995;49:S3-S8.
16. Department of Environment Transport and the Regions. Measuring multiple deprivation at the small area level: the indices of deprivation. London: DETR, 2000.
17. National Assembly for Wales. Welsh Index of Multiple Deprivation. National Assembly for Wales, Cardiff, 2000.
18. Office for National Statistics. 1991 Census: small area statistics and local base statistics; 1991. Report No. 1.
19. Penhale B, Noble M. Ward level population estimates mid-1998. Oxford: Social Disadvantage Research Group, Department of Policy and Social Work, University of Oxford, 2000.
20. Office for National Statistics. Census 2001 homepage. www.statistics.gov.uk/census 2001/, accessed 20 December 2004
21. Woods LM, Rachet B, Riga M, Stone N, Shah A, Coleman MP. Geographical variation in life expectancy at birth in England and Wales is largely explained by deprivation. J Epidemiol Community Health. 2005;59:115-120.
22. Berkson J, Gage RP. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clinic. 1950;25:270-286.
23. Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990;9:529-538.
24. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51-64.
25. StataCorp. STATA statistical software [7.0]. 1997, College Station, TX: STATA Corporation.
26. Sant M, Allemani C, Berrino F, ColemanMP, Aareleid T, Chaplain G et al. Breast carcinoma survival in Europe and the USA: a population-based study. Cancer. 2004;100:715-722.
27. Gatta G, Ciccolallo L, Capocaccia R, Coleman MP, Hakulinen T, Møller H et al. Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer. 2003; 39:2214-2222.
28. Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Berrino F. Childhood cancer survival in Europe and the United States. Cancer. 2002;95:1767-1772.
29. Gatta G, Capocaccia R, Coleman MP, Ries LAG, Hakulinen T, Micheli A et al. Toward a comparison of survival in American and European cancer patients. Cancer. 2000;89:893-90031.
30. Coleman MP, Babb P, Damiecki P, Grosclaude P, Honjo S, Jones J et al. Cancer survival trends in England and Wales, 1971-1995: deprivation and NHS Region. London: The Stationary Office; 1999:449-456.
31. Finger PT. Do you speak ocular tumor? Ophthalmology. 2003;110:13-4.
32. Brenner H, Arndt V. Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. Cancer Causes Control. 2004;Nov;15(9):903-910.
33. Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt. 2001;21:268-271.
34. Ah-Fat FG, Damato BE. Delays in the diagnosis of uveal melanoma and effect on treatment. Eye. 1998;12(pt5):781-782.
35. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245-250.
36. Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients. Acta Ophthalmol Scand. 1999;77:414-417.
37. Kroll S, Char DH, Quivey J, Castro J. A comparison of causespecific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. Ophthalmology. 1998;105:2035-2045.
38. Damato B, Lecuona K. Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients. Ophthalmology. 2004;111:977-983.
39. Hungerford JL. Current trends in the treatment of ocular melanoma by radiotherapy. Clin Exp Ophthal. 2003;31:8-13.
40. Zimmerman LE, McLean IW. An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol. 1979;87(6):741-760.
41. Singh AD, Rennie IG, Kivela T, et al. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004;88(7):962-967.
42. Eskelin S, Pyrhonen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443-1449.
43. Woods LM, Rachet B, Coleman MP. Choice of geographic unit influences socioeconomic inequalities in breast cancer survival. Br J Cancer. 2005;92:1279-1282.
44. Fraser S, Bunce C, Wormald R, Brunner E. Deprivation and late presentation of glaucoma: case-control study. Br Med J. 1998;322(7287):639-643.
45. Bullard J, Coleman MP, Robinson D, Luk J-M, Bell J, Peto J. Completeness of cancer registration: a new method for routine use. Br J Cancer. 2000;82:1111-1116.